natgillin/translations-raw huggingface dataset:
or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6alkyl, C1-6haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl and heterocycloalkyl; 
ili Rc i Rd zajedno sa atomom dušika na koji su spojeni formiraju 4-, 5-, 6- ili 7-članu heterocikloalkilnu grupu opcionalno supstituiranu sa 1, 2, ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 haloalkila, arila, arilalkila, heteroarila, heteroarilalkila, cikloalkila i heterocikloalkila;
is oxygen; X is optionally substituted aryl; 
Arje kisik; X je opcionalno supstituirani aril;
A container according to claim 7, wherein the distance between the upper surface of the denesting area and the base of the tray is shorter than the distance between the upper surface of the flange and the base. 
Posuda prema patentnom zahtjevu 7, pri čemu je razmak između gornje površine zone za odvajanje 1 osnove posude manji od razmaka između gornje površine prirubnice i osnove.
detecting the formation of or determining the amount of a complex between the agent and the nucleic acid or the tumor-associated antigen. 
(ii) detekciju formiranja ili određivanje količine kompleksa između sredstva i nukleinske kiseline ili antigena koji je povezan sa tumorom.
Heteromolecular metal complexes (chelates) disclosed in claim 1 or 2, wherein molecule A is a humic acid that has been treated with an amine in a step subsequent to the formation of the heteronuclear complex. 
Heteromolekularni metalni kompleksi (kelati) otkriveni u zahtjevima 1 do 7, naznačeni time što je molekula A huminska kiselina koja je bila tretirana sa aminom u koraku koji je uslijedio nakon tvorbe heteronuklearnog kompleksa.
The component (B) is known. 
(B) spoj ciprodinil.
The soft chewable veterinary composition of claim 5, wherein the binder is polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, a co-polymer of vinyl acetate and vinylpyrrolidone, or a polyethylene glycol, or a combination thereof, more preferably, polyvinylpyrrolidone or a polyethylene glycol, or a combination thereof. 
Mekani veterinarski pripravak za žvakanje prema zahtjevu 5, naznačen time, da vezivo je polivinilpirolidon, kopolimer vinilacetata i vinilpirolidona, ili polietilen-glikol, ili njihove kombinacije. Mekani veterinarski pripravak za žvakanje prema zahtjevu 5, naznačen time, da vezivo je polivinilpirolidon, ili polietilen-glikol, ili njihove kombinacije.
is hydrogen, C1 to C6 alkyl, phenyl unsubstituted or substituted by C1 to C6 alkyl, COR6 acyl group (R6 being hydrogen; C1 to C6 straight chain or branched alkyl; phenyl or benzoyl respectively unsubstituted or substituted by C1 to C6 alkyl), or any group leading to hydroxyl upon biological metabolization or chemical deprotection; and salts thereof; for prophylaxis and/or treatment of benign prostate hypertrophy or prostate carcinoma. 
Ru je vodik, C, do Cg alkil, fenil nesupstituiran ili supstituiran s C, do Cg alkilom, COR; acilnom skupinom (Rs je vodik; C; do Cg ravnolančani ili razgranati alkil; odnosno fenil ili benzoil nesupstituiran ili supstituiran s C, do Cy alkilom), ili bilo kojom skupinom koja vodi do hidroksila nakon biološke razgradnje ili kemijskog uklanjanja zaštite; i njegove soli; za uporabu u prevenciji 1/ili liječenju karcinoma prostate.
Ulipristal acetate, or a metabolite thereof selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183, for use in treating or preventing leiomyomatosis or metastatic leiomyoma according to anyone of claims 1 to 3 wherein it is to be administered with a daily dosage of 5 to 15 mg. 
Ulipristal acetat, 1li bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB- 4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 4 pri čemu se primjenjuje u dnevnoj dozi od 10 mg.
The marking device according to claim 1, wherein holes of the plurality of holes of the perforated sheet have a circular shape. 
Uređaj sukladno zahtjevu 1, gdje perforirani list sadrži veći broj ovalno oblikovanih rupa.
The composition of claim 8, wherein the composition suitable for oral administration is in a unit dosage form, optionally wherein the dosage unit is a tablet, powder, pill, dragee, capsule, liquid, gel, syrup, elixir, slurry, or suspension. 
Pripravak prema zahtjevu 8, naznačen time, što se pripravak koji je prikladan za oralnu primjenu nalazi u obliku jedinične doze, pri čemu je jedinična doza opcionalno tableta, prah, pilula, dražeja, kapsula, tekućina, gel, sirup, eliksir, gusta otopina ili suspenzija.
Reaction mixture is quenched with water (15 mL) under ice cold condition and aqueous layer is extracted with dichloromethane (3x25 mL). 
Reakcijsku smjesu ugasi se vodom (15 ml) uz hlađenje ledom, a vodeni sloj ekstrahira diklormetanom (3 x 25 ml).
granulating the blended mixture obtained in step a) with water or with an aqueous solution of binder, previously prepared, when the binder is present in step a); 
granuliranja pomiješane smjese dobivene u koraku a) s vodom ili s prethodno pripravljenom vodenom otopinom veziva, kada je vezivo prisutno u koraku a); c)
Upper part 54 is designed to receive both the plunger 42 and a spring 56 provided there around. 
Gornji dio 54 je izveden tako, da prihvaća oboje, 1 klipnjaču 42 i oprugu 56 koja se nalazi oko klipnjače.
installing or blowing fibre or fibre cable into said at least one duct placed in said micro trench. 
- < instalaciju ili upuhivanje vlakana ili vlaknastog kabela u navedeni najmanje jedan kanal smješten u navedenom mikro-rovu.
Buprenorphine shares many of the actions, such as analgesia, of full µ opioid agonists. 
Buprenorfin dijeli mnoga djelovanja, kao što je analgezija, s potpunim (čistim) u opioidnim agonistima.
The tablet of claim 6 that comprises 150 mg ± 5% of the compound of Formula I. 
Tableta prema patentnom zahtjevu 6 koja sadrži 150 mg ± 5% spoja sa formulom I.
The firearm of claim 1 or 11-13, wherein the mobile mass (34) forms an angle of between about 10 and about 90 degrees with the longitudinal axis of the barrel (21) in its most lowered position. 
Vatreno oružje iz patentnog zahtjeva 1 ili 11-13, pri čemu pomična masa (34) tvori kut od približno 10 1 90 stupnjeva s uzdužnom osi spremnika (21) u svojoj najdonjoj poziciji.
In one embodiment, any excipients may be mixed into a dry homogenous mix before being added to the active material and fluid. 
Postupak sukladno patentnom zahtjevu 15, pri čemu su svi ekscipijensi pomiješani u suhu homogenu smjesu prije nego što se dodaju u aktivni materijal i tekućinu.
Progesterone for use in treating a traumatic brain injury, wherein said progesterone is prepared for administration to a human subject in at least one cycle of therapy, wherein said cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone, said two-level dosing regime comprising a first time period of at least 1 hour, wherein a higher hourly infusion dose of progesterone of about 0.1 mg/kg/hr to about 7.1 mg/kg/hr is administered to the subject, followed by a second time period, wherein a lower hourly infusion dose of progesterone of about 0.05 mg/kg/hr to about 5 mg/kg/hr is administered to said subject. 
Progesteron namijenjen upotrebi liječenju traumatske ozljede mozga, naznačen time što se navedeni progesteron pripravlja za primjenu na ljudskom subjektu u najmanje jednom ciklusu terapije, gdje se navedeni ciklus terapije sastoji u primjeni terapijski djelotvornog dvorazinskog intravenskog režima doziranja progesterona, gdje navedeni dvorazinski režim doziranja uključuje prvi period od najmanje 1 sata, gdje se na subjektu primijenjuje viša infuzijska doza progesterona po satu od otprilike 0,1 mg/kg/hr do otprilike 7,1 mg/kg/hr, za čim slijedi drugi period, gdje se na navedenom subjektu primijenjuje niža infuzijska doza progesterona po satu od otprilike 0,05 mg/kg/hr do otprilike 5 mg/kg/hr.
The dosage form of claim 1, further comprising rasagline base. The dosage form of claim 1, wherein up to 2% of the total amount of rasagiline in the dosage form is present as rasagiline free base. 
Sastav prema jednom od patentnih zahtjeva 7-10, naznačen time, da sadržaj rasagilina u obliku rasagilin citrata iznosi više od 50% ukupnog sadržaja rasagilina u sastavu.
Providing the vehicle application had no significant effect on tail current amplitude, a cumulative concentration effect curve to the compound was then constructed. 
Potom je, pod uvjetom da primjena nosača nije imala značaj utjecaj na amplitudu struje, izrađena krivulja kumulativnog učinka koncentracije.
The reaction of the compound of Formula II with the compound of Formula XVa may be carried out using analogous conditions to those described in process (a) above, followed by removal of the protecting group under standard conditions. 
Reakcija između spoja prikazanog Formulom II i spoja prikazanog Formulom XVa može se provesti pod analognim goreopisanim uvjetima opisanim za postupak (a), nakon čega slijedi uklanjanje zaštitne skupine pod standardnim uvjetima.
The unit dosage form according to claim 1, further comprising one or more pharmaceutically acceptable excipients. 
Jedinični dozirni oblik za uporabu prema zahtjevima 1 do 4, koji dalje sadrži jednu ili više farmaceutski prikladnih pomoćnih tvari.
The compound for use of any of claims 1-4, wherein the compound is formulated for administration from 10 days to 12 hours prior to the administration of the antibody, from 7 days to 12 hours prior to the administration of the antibody, from 5 days to 1 day prior to the administration of the antibody, or from 3 days to 1 day prior to the administration of the antibody. 
Spoj za primjenu prema zahtjevu 1, 3, ili 6, naznačen time što je spoj oblikovan za davanje od 10 dana do 12 sati prije davanja cjepiva, od 7 dana do 12 sati prije davanja cjepiva, od 5 dana do 1 dan prije davanja cjepiva, ili od 3 dana do 1 dan prije davanja cjepiva.
One example of this uses activation with methyl oxalyl chloride followed by reduction with tri-n-butyltin hydride and 2-[(cyano-dimethyl-methyl)-azo]-2-methyl-propionitrile (AIBN) as described by Hansen et al. Synthesis 1999, 1925-1930. 
Jedan takav primjer rabi aktivaciju metil oksalil kloridom i potom redukciju tri-x-butilin hidridom i 2-[(cijano-dimetil-metil)azo]-2-metil-pionitrilom (AIBN) prema opisu u Hansen i sur., Synthesis 1999., 1925-1930.
a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:113 and/or a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:112; 
(a) VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 113i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 112;
The pharmaceutical composition according to claim 8 or the formulation according to claim 9 showing a reduced number of sub-visible particles wherein said formulation has preferably less than 500, more preferably less than 300 sub-visible particles per vial, the particles having a size greater than 10 µm, the number of particles being determined according to USP 27, <788> Particulate matter in injections by light obscuration particle count test. 
Farmaceutski sastav prema zahtjevu 8 1li formulacija prema zahtjevu 9, naznačen(a) time, da pokazuje smanjeni broj sub-vidljivih čestica, dok spomenuta formulacija ima poželjno manje od 500, još bolje manje od 300 subvidljivih čestica po ampuli, pri čemu čestice imaju veličinu veću od 10 um, a količinski broj čestica se određuje prema USP 27, <788> Ispitivanje broja čestica putem laganog zatamnjenja za kruti materijal od čestica u injekcijama.
The compound of claim 2, wherein the compound is selected from the group consisting of 
Spoj prema zahtjevu 2, naznačen time što je spoj odabran iz skupine koju čine
The assembly according to claim 1, wherein said constricting ring comprises centering ribs (258) to guide said bottle into said pronged clamp during insertion. 
Sklop u skladu s patentnim zahtjevom 1, naznačen time što navedeni stezni prsten ima centrirajuća rebra (258) koja navode navedenu bocu u navedenu viličastu stezaljku tijekom umetanja.
The side 4 further comprises a lower inner element 14, which is attached to the outer part 10. 
Strana 4 nadalje ima donji unutarnji element 14 koji je pričvršćen na vanjski dio 10.
A method of estimating a fraction of fetal DNA in DNA obtained from a bodily fluid of a pregnant individual, the method comprising: 
Postupak procjene frakcije fetalne DNK u DNK dobivenoj iz tjelesne tekućine trudne osobe, te postupak sadrži:
The portable boot stirrup of claim 1 including a foam liner (23) positionable within said shell structure (18). 
Prenosiva udlaga za nogu u skladu s patentnim zahtjevom 1, naznačena time što ima i podstavu od pjene (23), koju se može namjestiti unutar navedene školjkaste strukture (18).
0.5 The above ingredients with the exception of the magnesium stearate are combined and mixed. 
0,5 Gore nabrojani sastojci, osim magnezijevog stearata, se kombinira i međusobno pomiješa.
is alkyl. The compound or therapeutically acceptable salt of claim 1, wherein the compound is selected from the group consisting of: 
Spoj ili terapeutski prihvatljiva sol u skladu s patentnim zahtjevom 1, naznačen time, da je spoj odabran iz skupine koju čine:
providing a second set of at least two track segments, each of the track segments of the second set being adjacent to at least another one of the track segments of the second set such that the second set of at least two track segments extends completely across a width of the sports track, the second set of at least two track segments occurring at a different position along the sports track than the first set of at least two track segments; 
dodatnom osiguravanju najmanje dva dodatna segmenta trkačke staze po širini sportske trkačke staze (2) na drugom položaju, gdje se najmanje dva dodatna segmenta trkačke staze nalaze jedan uz drugog po širini sportske trkačke staze, gdje se drugi položaj razlikuje od položaja najmanje dva segmenta trkačke staze u smjeru pružanja sportske trkačke staze;
and the third layer comprises 150 ± 8.0 mg of microcrystalline cellulose or lactose monohydrate, or a mixture thereof. 
Tableta zahtjeva 12 gdje treći sloj sadrži laktozu monohidrat i/ili mikrokristalnu celulozu.
Diphenyl sulphides of formula (XVI) and variations thereof have been disclosed as serotonin re-uptake inhibitors and have been suggested for use in treatment of depression, cf. e.g. U.S. Pat. No. 5,095,039, U.S. Pat. No. 4,056,632, EP 396827 A1 and WO 9312080. 
Difenil sulfidi formule (XVI) I njihove varijacije ustanovljeni su kao inhibitori re-apsorpcije serotonina I predloženi za korištenje kod liječenja depresije, npr. US 5095039, US 4556632 EP 396827 A1 1 WO 9312080, EP 402097 opisuju halogen susptituciju difenilsulfida za koje se tvrdi da su selektivni inhibitori re-apsorpcije serotonina kod liječenja depresije.
a heavy chain wherein the variable domain comprises the sequence shown in SEQ ID NO:28 for the CDRH1, the sequence shown in SEQ ID NO:29 or SEQ ID NO:34 for the CDRH2 and the sequence shown in SEQ ID NO:30 for the CDRH3 and 
teški lanac pri čemu varijabilna domena sadrži sekvencu prikazanu u SEK ID BR: 28 za CDRH1, sekvencu prikazanu u SEK ID BR: 29 ili SEK ID BR: 34 za CDRH2 i sekvencu prikazanu u SEK ID BR: 30 za CDRH3 i
Another embodiment includes a method of manufacturing a pharmaceutical composition comprising: recombinantly producing a therapeutic protein of interest using a host cell within a medium; filtering the medium using a CUNO depth filter with a positive charge; exposing the depth filter to a salt elution buffer with a conductivity of at least 20 mS/cm to release protein of interest from the filter; recovering released protein of interest from the salt elution buffer; recovering further protein of interest from the sample passed through the depth filter; and combining recovered protein of interest with pharmaceutically acceptable carriers thereby forming the pharmaceutical composition. 
Metoda za proizvodnju terapijskog sastava obuhvaća: rekombinantnu proizvodnju terapijskog proteina od interesa koristeći stanicu domaćina unutar medija; filtriranje medija koristeći dubinski filtar s pozitivnim nabojem; izlaganje dubinskog filtra soli elucijskog pufera provodljivosti od najmanje 20 mS/em zbog oslobađanja proteina od interesa iz filtra; obnavljanje oslobođenog proteina od interesa iz soli elucijskog pufera; obnavljanje daljnjeg proteina od interesa iz uzorka koji je prošao kroz dubinski filtar; kombiniranje obnovljenog proteina od interesa s farmaceutski prihvatljivim nosačima tako tvoreći farmaceutski sastav.
Determination of the Metabolic Clearance Rates of rFSH 
Datum objave europske prijave patenta:
A composition for cartilage tissue repair, the composition being prepared by mixing collagen having a diluted concentration of 5-60 mg/mL water or a physiological phosphate buffer solution; and hyaluronic acid having a diluted concentration of 5-20 mg/mL water or a physiological phosphate buffer solution using a two-way syringe or a mixer. 
PATENTNI ZAHTJEVI Pripravak za popravljanje hrskavičnog tkiva, naznačen time što se pripravak pripravlja miješanjem kolagena s razrijeđenom koncentracijom od 5-60 mg/ml vode ili otopine fiziološkog fosfatnog pufera; te hijaluronske kiseline s razrijeđenom koncentracijom od 5-20 mg/ml vode ili otopine fiziološkog fosfatnog pufera upotrebom dvosmjerne štrcaljke ili miješalice.
Evaluation of the Antioxidant Effect of MAAs 
Broj objave europskog patenta:
A process for preparing a crystalline freebase (Form III) of the compound of formula I: the process comprising the steps of: 
PATENTNI ZAHTJEVI M» Postupak za pripravu kristalne slobodne baze (Oblik III) spoja formule I:
In a preferred embodiment the pharmaceutical composition according to the invention the adjuvant is selected from the group consisting of colony-stimulating factors, such as Granulocyte Macrophage Colony Stimulating Factor (GM-CSF, sargramostim), immiquimod and resimiquimod. 
Farmaceutski sastav prema zahtjevu 5, gdje je adjuvans odabran iz skupine koja sadrži čimbenike za poticanje kolonija kao što su čimbenik za poticanje granulocitnih i makrofagnih kolonija (GM-CSF), odnosno imikvimod ili resikvimod.
In a preferred embodiment the melt flow index (MFI) of the polymer on which the melt layer is based is above 25 g/10 min, preferably 100 g/10 min or higher, particularly preferably above 100 g/10 min (in accordance with ISO 1133, 230° C., 2.16 kg). 
* kombinacije homopolipropilena i kopolimera propilena, pri čemu je lagano tekući poliolefin sastavljen samo od nepolarnog monomera i ima indeks tečenja taljevine (MFI) od 100 g/10 min (po ISO 1133, 230"C, 2,16 kg) ili više, i ima indeks tečenja taljevine (MFI) homopropilena od 100 g/10 min (po ISO 1133, 230"C, 2,16 kg) ili više.
electrically drive said active load (50) so as to reduce said dissipation current (ID) and stop the overheating condition; and 
električno pogonjenje navedenog aktivnog tereta (50) kako bi se oslabilo navedenu struju rasipanja (Ip) i zaustavilo stanje pregrijavanja; i
vinyl aromatic polymers and/or vinyl aromatic copolymers in an amount equal to at least 10% by weight, calculated with respect to the overall composition, 
vinilaromatske polimere i/ili vinilaromatske kopolimere u količini koja iznosi najmanje 10%, težinski, zračunato s obzirom na ukupnu mješavinu,
Activities of the compounds of Table 3 Cmpd 
Datum podnošenja europske prijave patenta:
contacting the trans-(+)-A9-tetrahydrocannabinol from step (b) with trans-(-)-A9-tetrahydrocannabinol and a non-polar organic solvent to form the first composition. 
kontaktiranje trans-(+)-A9-tetrahidrokanabinola iz koraka (b) sa trans-(-)-A9-tetrahidrokanabinolom i nepolarnim organskim otapalom da formiraju prvi sastav.
A method for treating or preventing bacterial infections or disorders associated with bacterial infections in an animal, wherein the method comprises administering to the animal a therapeutically effective amount of the compound according to claim 1 . 
Spoj u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju bakterijskih infekcija 1li poremećaja povezanih s bakterijskim infekcijama kod životinje.
A method of ameliorating HIV comprising administering to a mammal an antiviral effective amount of a compound of Formula I, including pharmaceutically accceptable salts thereof, as claimed in claim 1, and one or more pharmaceutically acceptable carriers, excipients or diluents. 
Farmaceutska smjesa, naznačena time što sadrži spoj Formule 1 u količini koja je učinkovita protiv virusa, uključujući njegove farmaceutski prihvatljive soli, u skladu sa zahtjevom 1, i jedan ili više farmaceutski prihvatljivih nosača, pomoćnih tvari ili punila.
is selected from H and optionally substituted C1-C8 alkyl, herein said optional substituents are one to three R10 groups; 
R"' je odabran od H i proizvoljno supstituiran C,-Ca alkilom, pri čemu su navedeni nezavisni supstituenti jedna do tri R!" skupine;
A composition comprising a muscarinic receptor agonist selected from the group consisting of pilocarpine, cevimeline, carbachol, methacholine, and bethanechol, or a salt thereof and an inhibitor of thyroid hormone synthesis selected from the group consisting of methimazole, carbimazole, propylthiouracil and amiodarone, or a salt thereof, and a pharmaceutically acceptable carrier or excipient. 
PATENTNI ZAHTJEVI Sastav obuhvaća agonista muskarinskih receptora odabranog iz grupe koja se sastoji od pilokarpina, cevimelina, karbakola, metakolina i betanekola, ili njihovih soli, 1 inhibitora sinteze hormona štitnjače odabranog iz grupe koja se sastoji od metimazola, karbimazola, propiltiouracila i amiodarona, ili njihovih soli, i farmaceutski prihvatljivi nosač ili ekscipijens.
In which case, the data transmission device may be supplied directly with a pointer indicating the location of the telegram for transmission within the telegram memory. 
U kojem slučaju, naprava za prijenos podataka može se opskrbiti izravno pokazivačem koji indicira lokaciju telegrama za prijenos unutar memorije telegrama.
wherein: A represents a single bond, an oxygen atom, a sulfur atom, NH, or CH2; 
A predstavlja jednostruku vezu, kisikov atom, sumporov atom, NH, ili CH2;
So, according to one embodiment of the present invention, it is provided that the board-like, plane pieces of wood are glued on each other to a parquet in the manner of a herringbone pattern. In such herringbone patterns, the fiber directions of some pieces of wood are in parallel to each other, while the fiber directions of other pieces of wood are transverse to each other, what results in pleasing optical effects having a minimum of complexity. 
Tako je, u skladu s jednim ostvarenjem predmetnog izuma, osigurano da se ravni komadi od drva koji imaju oblik ploče lijepe jedan na drugi da bi se dobio parket koji ima uzorak kosti od haringe, pri čemu su u takvim uzorcima kosti od haringe, smjerovi vlakana nekih komada od drva paralelni jedni s drugima, dok su smjerovi vlakana drugih komada od drva popreko jedni na druge, što ima za posljedicu postizanje optičkog efekta koji ima minimalnu složenost.
With reference to the figures, the reference numeral 1 indicates a ski boot comprising a rigid conventional-type sole 2. 
Na slikama, usporedbeni broj 1 označava cipelu za skijanje koja obuhvaća kruti konvencionalan tip potplata 2.
(viii) a cumulative total amount of tyrosine per unit volume greater than 2.0 mM; and 
(viii) kumulativna ukupna količina tirozina po jedinici volumena veća od približno 2,0 mM.